Trial · NCT01856530

Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder

NCT01856530, Phase 1, Phase 2, Completed, Stefan G. Hofmann; results first posted 2014-08-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder. Trials, record NCT01856530. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01856530

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder
NCT number: NCT01856530
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 60 participants, actual
Lead sponsor: Stefan G. Hofmann
Conditions: Social Anxiety Disorder
Interventions: Oxytocin, Placebo
First posted: 2013-05-17
Last updated: 2018-02-13
Results first posted: 2014-08-15

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Social Cooperation	Day 1 (first day oxytocin or placebo was administered)	The outcome measure involved difference scores in the number of balls tossed to Player 1 between two conditions of the task. Across both conditions, the participant (always assigned as "Player 2") played with 3 other on-line players in real time. In Condition 1, Player 1 was programmed to toss on average 70% of his balls to the participant. In Condition 2, Player 1's behavior switched such that he was programmed to toss on average only 10% of his balls to the participant. The data reported below is the number of balls tossed to Player 1 in Condition 2 minus balls tossed under Condition 1.
Primary	Disengagement From Social Threat Cues	Day 1 (first day oxytocin or placebo was administered)	The outcome measure involved difference scores in response latencies on disengagement trials for disgust versus neutral cues. Difference scores were calculated as response latencies during disengagement trials for disgust cues minus response latencies during disengagement trials for neutral cues. Negative change scores represent an improvement in disengagement.
Secondary	Perceived Trust Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Participants will rate their perceived level of trust (on a 1-7 Likert scale) toward Player 1 during online ball-tossing task. Higher ratings on this scale reflect greater perceived trust toward Player 1.
Secondary	Perceived Empathy Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Participants will rate their level of perceived empathy (on a 1-7 Likert scale) with Player 1 during online ball-tossing task. Higher scores on this scale reflect greater perceived empathy toward Player 1.
Secondary	Perceived Preference Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Participants will rate their level of preference (on a 1-7 Likert scale) for Player 1 during online ball-tossing task. Higher scores on this scale reflect greater preference for Player 1.
Secondary	Perceived Rejection Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Participants will rate their level of perceived rejection (on a 1-7 Likert scale) from Player 1 during online ball-tossing task. Higher scores on this scale reflect greater perceived rejection from Player 1.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Social Cooperation	Day 1 (first day oxytocin or placebo was administered)	Data from 2 participants could not be analyzed due to technical difficulties with the computer task. Thus, the number of participants analyzed was 52 in total, rather than 54.	Ball tosses	MEAN
PRIMARY	Disengagement From Social Threat Cues	Day 1 (first day oxytocin or placebo was administered)		Milliseconds	MEAN
SECONDARY	Perceived Trust Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Due to technical difficulties during the computer task, two participants did not complete this questionnaire and were not included in the analysis. Thus, only 52 participants were included in this analysis.	units on a scale	MEAN
SECONDARY	Perceived Empathy Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Due to technical difficulties during the computer task, two participants did not complete this questionnaire and were not included in the analysis. Thus, only 52 participants were included in this analysis.	units on a scale	MEAN
SECONDARY	Perceived Preference Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Due to technical difficulties during the computer task, two participants did not complete this questionnaire and were not included in the analysis. Thus, only 52 participants were included in this analysis.	units on a scale	MEAN
SECONDARY	Perceived Rejection Scores on a 1-7 Likert Scale	Day 1 (first day oxytocin or placebo was administered)	Due to technical difficulties during the computer task, two participants did not complete this questionnaire and were not included in this analysis. Thus, only 52 participants were included in this analysis.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Social Cooperation	Oxytocin	4.42	Standard Deviation 6.706	Ball tosses
Social Cooperation	Placebo	4.69	Standard Deviation 6.078	Ball tosses
Disengagement From Social Threat Cues	Oxytocin	1.34	Standard Deviation 36.79	Milliseconds
Disengagement From Social Threat Cues	Placebo	-2.69	Standard Deviation 52.39	Milliseconds
Perceived Trust Scores on a 1-7 Likert Scale	Oxytocin	4.65	Standard Deviation 1.47	units on a scale
Perceived Trust Scores on a 1-7 Likert Scale	Placebo	4.73	Standard Deviation 1.12	units on a scale
Perceived Empathy Scores on a 1-7 Likert Scale	Oxytocin	4.46	Standard Deviation 1.39	units on a scale
Perceived Empathy Scores on a 1-7 Likert Scale	Placebo	4.27	Standard Deviation 1.46	units on a scale
Perceived Preference Scores on a 1-7 Likert Scale	Oxytocin	5.04	Standard Deviation 1.40	units on a scale
Perceived Preference Scores on a 1-7 Likert Scale	Placebo	5.04	Standard Deviation 1.18	units on a scale

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oxytocin	27
Overall Study	STARTED	Placebo	27
Overall Study	COMPLETED	Oxytocin	27
Overall Study	COMPLETED	Placebo	27
Overall Study	NOT COMPLETED	Oxytocin	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Jitteriness/restlessness	Nervous system disorders	Oxytocin	4	27
other	Jitteriness/restlessness	Nervous system disorders	Placebo	5	27
other	Anxiety	Nervous system disorders	Oxytocin	3	27
other	Anxiety	Nervous system disorders	Placebo	3	27
other	Dry mouth	Nervous system disorders	Oxytocin	2	27
other	Dry mouth	Nervous system disorders	Placebo	2	27

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Oxytocin
Total, all-cause mortality	Placebo
Total, other adverse events	Oxytocin	7	27
Total, other adverse events	Placebo	9	27
Total, serious adverse events	Oxytocin	0	27
Total, serious adverse events	Placebo	0	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
28559206	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Oxytocin vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01856530

GET https://conductscience.org/api/trials/v1/NCT01856530/registered

API reference For AI assistants